VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Down 54.7% in March

VivoSim Labs, Inc. (NASDAQ:VIVS) saw a large decline in short interest in March. As of March 13th, there was short interest totaling 14,885 shares, a decline of 54.7% from the February 26th total of 32,826 shares. Based on an average daily trading volume, of 60,908 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.6% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VivoSim Labs in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Trading of VivoSim Labs

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs at the end of the most recent reporting period. Institutional investors and hedge funds own 8.23% of the company’s stock.

VivoSim Labs Price Performance

NASDAQ:VIVS opened at $1.62 on Friday. The company has a market cap of $4.23 million, a price-to-earnings ratio of -0.51 and a beta of 1.25. VivoSim Labs has a 1 year low of $1.41 and a 1 year high of $5.30. The stock’s 50 day simple moving average is $1.97 and its two-hundred day simple moving average is $2.34.

VivoSim Labs (NASDAQ:VIVS) last announced its earnings results on Wednesday, February 11th. The company reported ($1.03) earnings per share (EPS) for the quarter. VivoSim Labs had a negative net margin of 861.27% and a negative return on equity of 15.51%. The business had revenue of $0.03 million for the quarter.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.